Monopar Therapeutics Inc

Monopar Therapeutics Inc. pioneers oncology drug combos to boost patient outcomes, trading at $82.58 on Nasdaq with a $601 M market cap—discover its research, investor outlook, and global cancer impact.

Monopar Therapeutics Inc.’s stock has experienced significant fluctuations over the past year, closing at $34.505 on June 9, 2025, with a market capitalization of approximately $226.94 million.

Monopar Therapeutics Inc.’s stock has experienced significant fluctuations over the past year, closing at $34.505 on June 9, 2025, with a market capitalization of approximately $226.94 million.

Monopar Therapeutics Inc. is advancing in cancer drug development, with a focus on improving clinical outcomes for patients through innovative research and drug combinations.